Pennsylvania Hematology Oncology Associates (Philadelphia, PA) › P2B-037

P2B-037

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Phase II
Pennsylvania Hematology Oncology Associates (Philadelphia, PA) · Dr. Tanaka
consented 2012-09-23

completed

AEs

Serious

Dropout signal

–

Adverse events

Grade 2 nausea with onset in cycle 2 (2012-11-07); assessed as not related to study drug (not related); resolved 2012-11-11.

moderate assessed

Grade 1 vomiting with onset in cycle 2 (2012-11-06); assessed as not related to study drug (not related); resolved 2012-11-09.

mild assessed

Grade 1 anaemia with onset in cycle 1 (2012-10-23); assessed as related to study drug (probable); not resolved at last follow-up.

mild assessed

Grade 3 urinary tract infection with onset in cycle 1 (2012-10-13); serious (hospitalization); assessed as not related to study drug (unlikely); resolved 2012-10-22.

severe serious assessed

Data queries

No data queries. Open queries would appear here for this patient.